Entera Bio Ltd. Balance Sheet
ENTX|5 years of annual SEC 10-K data (FY2021-FY2025)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 5 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Total Assets
$16M
FY2025
Cash
$7M
Cash and equivalents
Total Debt
N/A
FY2025
Shareholder Equity
$8M
FY2025
Entera Bio Ltd. had $16M in total assets and $8M in shareholders' equity as of FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score NaN (distress zone, below 1.23 threshold)
- Piotroski F-Score: 2/9 criteria passed
- Currently unprofitable: Net income is negative
- Cash-backed earnings: Operating cash flow exceeds net income
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | $7.1M | $8.7M | $11.0M | $12.3M | $24.9M |
| Accounts Receivable | - | $126.0K | $0 | $246.0K | $183.0K |
| Current Assets | $15.3M | $9.0M | $11.3M | $12.8M | $25.3M |
| PP&E (Net) | $134.0K | $57.0K | $100.0K | $139.0K | $156.0K |
| Total Assets | $16.0M | $9.4M | $11.8M | $13.1M | $26.0M |
| Current Liabilities | $2.2M | $1.2M | $1.1M | $1.3M | $3.2M |
| Shareholders' Equity | $8.1M | $10.4M | $11.8M | $22.6M | $7.5M |